 |
市場調査レポート
商品コード
1321856
PD-1およびPD-L1阻害剤の世界市場 - 市場規模、シェア、成長分析：タイプ別（PD-1阻害剤、PD-L1阻害剤）、用途別（癌、自己免疫疾患）、エンドユーザー別（病院、クリニック）、業界予測（2023年～2030年）Global PD-1 And PD-L1 Inhibitors Market Size, Share, Growth Analysis, By Type(PD-1 inhibitors, and PD-L1 inhibitors), By Application(Cancer, Autoimmune Diseases), By End-User(Hospitals, Clinics) - Industry Forecast 2023-2030 |
||||||
| PD-1およびPD-L1阻害剤の世界市場 - 市場規模、シェア、成長分析：タイプ別（PD-1阻害剤、PD-L1阻害剤）、用途別（癌、自己免疫疾患）、エンドユーザー別（病院、クリニック）、業界予測（2023年～2030年） |
|
出版日: 2023年07月16日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界のPD-1およびPD-L1阻害剤の市場規模は、2021年に303億米ドル、2022年には356億米ドルとなりました。同市場は、予測期間（2023年～2030年）にかけ17.5%のCAGRで拡大し、2030年には1,293億6,000万米ドルに成長すると見込まれています。
世界のPD-1およびPD-L1阻害剤市場は、癌の有病率の上昇と免疫療法治療の採用増加により、著しい成長を遂げています。PD-1阻害剤とPD-L1阻害剤は、免疫系の調節に重要な役割を果たし、免疫系が癌細胞を認識して効果的に攻撃できるようにします。これらの阻害剤は、様々な癌種で有望な結果を示しており、腫瘍学での普及につながっています。製薬業界の主な参入企業は、革新的なPD-1およびPD-L1阻害剤を導入するために研究開発に投資しており、市場の拡大をさらに促進しています。
PD-1およびPD-L1阻害剤市場を促進する主な要因の1つは、癌の罹患率の上昇です。世界中で様々な種類の癌の有病率が増加しているため、効果的で標的を絞った免疫療法治療に対する需要が高まっています。PD-1阻害剤とPD-L1阻害剤は、免疫系が癌細胞を認識し、より効果的に闘うために重要な役割を果たすことから、癌との闘いにおいて有望な治療選択肢として浮上しています。その結果、癌の発生件数の増加が、癌領域におけるPD-1阻害剤とPD-L1阻害剤の採用に拍車をかけ、市場の成長を促進しています。
PD-1およびPD-L1阻害剤市場が直面する抑制要因のひとつは、薬剤コストの上昇です。高度な免疫療法であるPD-1阻害薬とPD-L1阻害薬は開発・製造コストが高く、その結果、患者の治療費が高くなる可能性があります。このコスト要因は、一部の患者にとって救命治療へのアクセスを制限し、癌治療におけるPD-1およびPD-L1阻害剤の全体的な普及に影響を及ぼす可能性があります。製薬企業やヘルスケアプロバイダーは、こうした革新的な治療法をより広く普及させ、手頃な価格で利用できるようにするため、この課題に対処する必要があります。
当レポートは、世界のPD-1およびPD-L1阻害剤市場について調査し、市場の概要とともに、タイプ別、用途別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。
目次
エグゼクティブサマリー
親市場分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 主要な市場洞察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- 知財分析
- 貿易分析
- スタートアップ分析
- 原材料分析
- イノベーションマトリックス
- パイプライン製品の分析
- マクロ経済指標
- トップの投資分析
- 主要な成功要因
- 競合の程度
- 市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制状況
- ポーターズ分析
世界のPD-1およびPD-L1阻害剤市場、タイプ別
- 市場概要
- PD-1阻害剤
- PD-L1阻害剤
世界のPD-1およびPD-L1阻害剤市場、用途別
- 市場概要
- 癌
- 自己免疫疾患
- その他
世界のPD-1およびPD-L1阻害剤市場、エンドユーザー別
- 市場概要
- 病院
- クリニック
- その他
世界のPD-1およびPD-L1阻害剤市場、地域別
- 市場概要
- 北米
- 欧州
- アジア太平洋
- ラテンアメリカ
- 中東・アフリカ
競合情勢
- 主要企業プロファイル
- AstraZeneca
- BeiGene
- BioInvent
- Bristol-Myers Squibb
- CStone Pharmaceuticals
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Incyte Corporation
- Innovent Biologics
- Jiangsu Hengrui Medicine
- Kyowa Kirin
- Merck & Co.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals
- Sanofi S.A
- Shanghai Junshi Biosciences
- Sorrento Therapeutics
- Takeda Pharmaceutical Company Limited
- TG Therapeutics
Market Insights
Global PD-1 And PD-L1 Inhibitors Market size was valued at USD 30.3 billion in 2021 and is poised to grow from USD 35.6 billion in 2022 to USD 129.36 billion by 2030, growing at a CAGR of 17.5% in the forecast period (2023-2030).
The global PD-1 and PD-L1 inhibitors market is witnessing significant growth due to the rising prevalence of cancer and the increasing adoption of immunotherapy treatments. PD-1 and PD-L1 inhibitors play a crucial role in the modulation of the immune system, enabling it to recognize and attack cancer cells effectively. These inhibitors have shown promising results in various cancer types, leading to their widespread use in oncology. Key players in the pharmaceutical industry are investing in research and development to introduce innovative PD-1 and PD-L1 inhibitors, further propelling market expansion.
Top-down and bottom-up approaches were used to estimate and validate the size of PD-1 And PD-L1 Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global PD-1 And PD-L1 Inhibitors Market Segmental Analysis
PD-1 And PD-L1 Inhibitors Market is segmented by type, application, and end-user. Based on type, the PD-1 And PD-L1 Inhibitors Market can be segmented into PD-1 inhibitors, and PD-L1 inhibitors. Based on application, the PD-1 And PD-L1 Inhibitors Market can be segmented into cancer, autoimmune diseases, and others. Based on end-users, the PD-1 And PD-L1 Inhibitors Market is segmented into hospitals, clinics, and others. Based on region, the PD-1 And PD-L1 Inhibitors Market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Driver
One of the key drivers propelling the PD-1 and PD-L1 inhibitors market is the increasing incidence of cancer. The growing prevalence of various types of cancer worldwide has led to a greater demand for effective and targeted immunotherapy treatments. PD-1 and PD-L1 inhibitors have emerged as promising therapeutic options in the fight against cancer, as they play a crucial role in enabling the immune system to recognize and combat cancer cells more effectively. As a result, the rising occurrence of cancer has fueled the adoption of PD-1 and PD-L1 inhibitors in oncology, driving market growth.
Restraints
One of the restraints faced by the PD-1 and PD-L1 inhibitors market is the escalating cost of these drugs. As advanced immunotherapies, PD-1 and PD-L1 inhibitors can be expensive to develop and produce, resulting in higher treatment costs for patients. This cost factor may limit access to these life-saving treatments for some individuals, affecting the overall adoption of PD-1 and PD-L1 inhibitors in cancer therapy. Pharmaceutical companies and healthcare providers need to address this challenge to ensure wider accessibility and affordability of these innovative therapies.
Market Trends
In the global PD-1/PD-L1 inhibitors market is the increasing emphasis on combination therapies. Evidence suggests that combining PD-1/PD-L1 inhibitors with other drugs, such as chemotherapy or other immunotherapies, can enhance their efficacy and mitigate the risk of resistance. Major market players are making substantial investments in the development of such combination therapies, with numerous new regimens currently undergoing clinical trials. This trend is anticipated to persist in the future as researchers and healthcare professionals strive to enhance patient outcomes and overcome the limitations of using PD-1/PD-L1 inhibitors as standalone treatments.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
- Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
- Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global PD-1 And PD-L1 Inhibitors Market by Type
- Market Overview
- PD-1 inhibitors
- and PD-L1 inhibitors
Global PD-1 And PD-L1 Inhibitors Market by Application
- Market Overview
- Cancer
- Autoimmune Diseases
- and Others
- Global PD-1 And PD-L1 Inhibitors Market by End-User
- Market Overview
- Hospitals
- Clinics
- and Others
- Global PD-1 And PD-L1 Inhibitors Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
- Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
- Key Company Profiles
- AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BeiGene
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioInvent
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CStone Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Incyte Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Innovent Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Jiangsu Hengrui Medicine
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kyowa Kirin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shanghai Junshi Biosciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sorrento Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- TG Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
